~~<i id='C1CB0F97CE'><strike id='C1CB0F97CE'><tt id='C1CB0F97CE'><pre id='C1CB0F97CE'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：leisure time 2025-10-04 03:50:08 Page View：58

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： European regulators recommend Amylyx's ALS drug be rejected
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

Wikipedia

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Life sciences deals on track to hit lowest point since 2017

AdobeIt’snosecretthatbiotechindustryfundinghasfallenfromitsCovidhighs.Butwithjustafewmonthsleftinthe

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Morphosys mixed study results for blood cancer drug

AdobeLONDON—AnexperimentalbloodcancerdrugfromMorphoSyshititsprimarytargetinapivotaltrial,thecompanya